MX2020008096A - Peptidos de la cadena b de la relaxina lipidados modificados y su uso terapeutico. - Google Patents

Peptidos de la cadena b de la relaxina lipidados modificados y su uso terapeutico.

Info

Publication number
MX2020008096A
MX2020008096A MX2020008096A MX2020008096A MX2020008096A MX 2020008096 A MX2020008096 A MX 2020008096A MX 2020008096 A MX2020008096 A MX 2020008096A MX 2020008096 A MX2020008096 A MX 2020008096A MX 2020008096 A MX2020008096 A MX 2020008096A
Authority
MX
Mexico
Prior art keywords
sub
relaxin
therapeutic use
chain peptides
lipidated
Prior art date
Application number
MX2020008096A
Other languages
English (en)
Spanish (es)
Inventor
Olivier Duclos
Sergio Mallart
Elisabetta Bianchi
Stéphane Illiano
Claire Minoletti-Hochepied
Raffaele Ingenito
Paola Magotti
Alessia Santoprete
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2020008096A publication Critical patent/MX2020008096A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2020008096A 2018-01-31 2019-01-30 Peptidos de la cadena b de la relaxina lipidados modificados y su uso terapeutico. MX2020008096A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18305094 2018-01-31
PCT/EP2019/052298 WO2019149782A1 (en) 2018-01-31 2019-01-30 Modified lipidated relaxin b chain peptides and their therapeutic use

Publications (1)

Publication Number Publication Date
MX2020008096A true MX2020008096A (es) 2020-09-24

Family

ID=61223862

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008096A MX2020008096A (es) 2018-01-31 2019-01-30 Peptidos de la cadena b de la relaxina lipidados modificados y su uso terapeutico.

Country Status (29)

Country Link
US (3) US10961295B2 (cg-RX-API-DMAC7.html)
EP (1) EP3746467B1 (cg-RX-API-DMAC7.html)
JP (1) JP7295871B2 (cg-RX-API-DMAC7.html)
KR (1) KR102755938B1 (cg-RX-API-DMAC7.html)
CN (1) CN111770934B (cg-RX-API-DMAC7.html)
AR (1) AR114325A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019214358B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020014834A2 (cg-RX-API-DMAC7.html)
CA (1) CA3089657A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020008308A2 (cg-RX-API-DMAC7.html)
DK (1) DK3746467T3 (cg-RX-API-DMAC7.html)
ES (1) ES3058633T3 (cg-RX-API-DMAC7.html)
FI (1) FI3746467T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20260016T1 (cg-RX-API-DMAC7.html)
IL (2) IL276170B2 (cg-RX-API-DMAC7.html)
LT (1) LT3746467T (cg-RX-API-DMAC7.html)
MA (1) MA52994A (cg-RX-API-DMAC7.html)
MX (1) MX2020008096A (cg-RX-API-DMAC7.html)
MY (1) MY199821A (cg-RX-API-DMAC7.html)
NZ (1) NZ766762A (cg-RX-API-DMAC7.html)
PH (1) PH12020551118A1 (cg-RX-API-DMAC7.html)
PL (1) PL3746467T3 (cg-RX-API-DMAC7.html)
PT (1) PT3746467T (cg-RX-API-DMAC7.html)
RS (1) RS67606B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202006903WA (cg-RX-API-DMAC7.html)
SI (1) SI3746467T1 (cg-RX-API-DMAC7.html)
TW (1) TWI763972B (cg-RX-API-DMAC7.html)
UY (1) UY38069A (cg-RX-API-DMAC7.html)
WO (1) WO2019149782A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201912034UA (en) 2017-02-08 2020-02-27 Bristol Myers Squibb Co Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
WO2019149781A1 (en) * 2018-01-31 2019-08-08 Sanofi Modified lipidated relaxin b chain peptides and their therapeutic use
MY199821A (en) 2018-01-31 2023-11-23 Sanofi Sa Modified lipidated relaxin b chain peptides and their therapeutic use
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
WO2023028008A2 (en) * 2021-08-23 2023-03-02 River 2 Renal Corp. Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions
CA3231953A1 (en) 2021-09-15 2023-03-23 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
WO2023086913A2 (en) 2021-11-11 2023-05-19 Tectonic Therapeutic, Inc. Relaxin-2 fusion protein analogs and methods of using same
CN115998842B (zh) * 2022-09-02 2025-08-26 郑州大学第一附属医院 一种逆转肝星形细胞激活的仿生纳米药物及其应用
EP4713001A2 (en) 2023-05-18 2026-03-25 Tectonic Operating Company, Inc. Relaxin-2 fusion protein analogs and methods of using same
KR20250054870A (ko) * 2023-10-16 2025-04-24 (주)케어젠 피부 상태 개선 활성을 갖는 펩타이드 및 이의 용도

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110288011A1 (en) * 2008-12-05 2011-11-24 Jean-Paul Castaigne Peptide therapeutic conjugates and uses thereof
EP2460527A1 (en) * 2010-01-21 2012-06-06 Sanofi Pharmaceutical composition for treating a metabolic syndrome
EP2524915A1 (en) * 2011-05-20 2012-11-21 Sanofi 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors
AU2012280474A1 (en) * 2011-07-01 2014-01-16 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
TW201315739A (zh) * 2011-07-01 2013-04-16 拜耳智慧財產有限公司 鬆弛素(relaxin)融合多肽類及其用途
AU2012291972B2 (en) * 2011-08-04 2017-03-09 Pharis Biotec Gmbh Process for preparing human relaxin-2
WO2013177529A1 (en) * 2012-05-24 2013-11-28 Angion Biomedica Corp. Relaxin-like compounds and uses thereof
WO2015038938A1 (en) 2013-09-13 2015-03-19 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
CA2945838C (en) * 2014-04-17 2022-08-16 The Florey Institute Of Neuroscience And Mental Health Modified relaxin b chain peptides
HUE052977T2 (hu) * 2014-04-22 2021-06-28 Txp Pharma Gmbh Elágazó szénláncú aminosav-próbával rendelkezõ peptid analóg(ok)
SG10201912034UA (en) * 2017-02-08 2020-02-27 Bristol Myers Squibb Co Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
TW201934572A (zh) * 2018-01-31 2019-09-01 法商賽諾菲公司 經修飾之鬆弛素b鏈胜肽及其治療用途
MY199821A (en) 2018-01-31 2023-11-23 Sanofi Sa Modified lipidated relaxin b chain peptides and their therapeutic use
WO2019149781A1 (en) * 2018-01-31 2019-08-08 Sanofi Modified lipidated relaxin b chain peptides and their therapeutic use
TWI844709B (zh) * 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
WO2023028008A2 (en) * 2021-08-23 2023-03-02 River 2 Renal Corp. Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions

Also Published As

Publication number Publication date
PL3746467T3 (pl) 2026-04-13
PT3746467T (pt) 2026-01-13
US20240218042A1 (en) 2024-07-04
CN111770934B (zh) 2024-10-18
US10961295B2 (en) 2021-03-30
AR114325A1 (es) 2020-08-19
AU2019214358A1 (en) 2020-08-20
CA3089657A1 (en) 2019-08-08
JP2021512099A (ja) 2021-05-13
US20190233494A1 (en) 2019-08-01
SI3746467T1 (sl) 2026-02-27
DK3746467T3 (da) 2026-01-12
RU2020126210A (ru) 2022-02-28
CN111770934A (zh) 2020-10-13
IL276170B2 (en) 2025-03-01
US11725036B2 (en) 2023-08-15
SG11202006903WA (en) 2020-08-28
IL276170B1 (en) 2024-11-01
UY38069A (es) 2019-08-30
TWI763972B (zh) 2022-05-11
KR102755938B1 (ko) 2025-01-20
NZ766762A (en) 2026-03-27
FI3746467T3 (fi) 2026-01-16
MA52994A (fr) 2021-05-05
US20210292387A1 (en) 2021-09-23
TW201940505A (zh) 2019-10-16
EP3746467B1 (en) 2025-10-08
HRP20260016T1 (hr) 2026-02-27
RS67606B1 (sr) 2026-01-30
BR112020014834A2 (pt) 2020-12-08
CO2020008308A2 (es) 2020-10-30
MY199821A (en) 2023-11-23
KR20200116085A (ko) 2020-10-08
AU2019214358B2 (en) 2023-05-25
LT3746467T (lt) 2026-01-26
IL316406A (en) 2024-12-01
IL276170A (en) 2020-09-30
ES3058633T3 (en) 2026-03-12
WO2019149782A1 (en) 2019-08-08
EP3746467A1 (en) 2020-12-09
PH12020551118A1 (en) 2021-07-05
JP7295871B2 (ja) 2023-06-21

Similar Documents

Publication Publication Date Title
PH12020551118A1 (en) Modified lipidated relaxin b chain peptides and their therapeutic use
MX2022006033A (es) Lipidos ionizables y composiciones de nanoparticulas de estos.
DOP2022000066A (es) Moduladores de sting (estimulador de genes de interferón)
MX2020007944A (es) Nanocomplejos similares a los lípidos y sus usos.
CY1119261T1 (el) Παραγωγα θειαζολιου
PE20241305A1 (es) Analogos de amilina
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
CL2019003892A1 (es) Nuevos derivados de azaquinolina.
PH12019500074A1 (en) Novel fatty acid modified urocortin-2 analogs for the treatment of diabetes and chronic kidney disease
CY1105362T1 (el) Παραγωγα σουλφοναμιδιου, η παρασκευη τους και η εφαρμογη αυτων ως φαρμακα
ATE254630T1 (de) Cyclosporine
AR114324A1 (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
AR114323A1 (es) Péptidos de la cadena b de la relaxina modificados y su uso terapéutico
SE0302192D0 (sv) Novel compounds
MX2022001678A (es) Derivados amidas hibridas de anfotericina b.
CL2019003441A1 (es) Puestos de mic-1 y usos de estos.
WO2017093810A3 (en) Composition for intraoral delivery of biologically active peptides and proteins
CL2021002621A1 (es) Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria
MX390044B (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia.
SA520420261B1 (ar) تركيبات إرنوماب واستخداماتها
SE0402925D0 (sv) Novel Compounds
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
EA202190217A1 (ru) Формы ивосидениба и фармацевтические композиции
HRP20250746T1 (hr) Peptidni spojevi i njihova terapijska upotreba
EA202090432A1 (ru) Новые соединения, активирующие путь nrf2